SecBot SecBot
Insider Cluster (2 insiders) ·Filed Nov 9, 2026

UTHR

UNITED THERAPEUTICS Corp
NEUTRAL
Impact 2/10
Horizonimmediate Processed7d 5h ago
Insider cluster: 2 insiders, $108K total
Actionable Insight • Neutral

The sales are routine 10b5-1 plan transactions and do not suggest insider concern about the business. Monitor the next 10-Q for any change in Tyvaso or Orenitram prescription trends, which are the key revenue drivers.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$588.61
T+0 close · Nov 9, 2026 · via day close
Latest settled
+1.20%
T+1 · $595.66
Vs SPY
−0.12%
α at T+1
Next horizon
T+5
in 8h
  1. T+0 · Nov 10 $588.61entry
  2. T+1 · 6d ago +1.20%α −0.12% · $595.66
  3. T+4 · todayOpen
  4. T+5 · in 8h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CEO Martine Rothblatt and EVP Paul Mahon sold a combined $108K in open-market sales under 10b5-1 plans, following the company's Q3 earnings report that showed revenue above consensus but EPS below due to a $130M in-process R&D charge. The sales are small relative to the $24.1B market cap (0.0004%) and appear to be routine plan-driven transactions, not a signal of deteriorating fundamentals.

Key Financial Metrics

Direction
selling
Total Value
$108.0K
Insiders
2

Key Facts

  • CEO Rothblatt sold $61K in open-market shares on Nov 6 under a 10b5-1 plan
  • EVP Mahon sold $47K in open-market shares on Nov 5 under a 10b5-1 plan
  • Total insider sales of $108K represent 0.0004% of UTHR's $24.1B market cap
  • Sales occurred 1-2 days after Q3 2026 earnings (revenue $832.5M, +4% YoY, above $781.1M consensus; GAAP EPS $5.71 below $6.04 consensus due to $130M IPR&D charge)
  • Both sales were under 10b5-1 plans, indicating pre-arranged trading schedules

Financial Impact

Insider sales of $108K total, immaterial relative to $24.1B market cap

Risk Factors

  • GAAP EPS missed consensus due to $130M IPR&D charge from Thymmune acquisition
  • CEO exercised 9,500 derivative shares at $0 and sold a portion, which is typical for tax and diversification planning

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-UTHR-1794264131457

Track record

123 reports on UTHR

Performance horizon

4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
  2. Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
  3. Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
  4. Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
  5. Nov 9, 20267d ago Insider Cluster Neutral 2/10 Viewing Entry $588.61 Now $587.88 −0.12% settles Nov 17
  6. Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
  7. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
  8. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
  9. Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
  10. Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
Showing 10 of 123

US Market Status

Market Closed · Opens Wed (10h 7m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026